Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis

Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis

Introduction: Tocilizumab and baricitinib are recommended treatment options for COVID-19 patients with hyperinflammatory response; however, there is a lack of systematic review directly evaluating their efficacy and safety.Objective: This review was conducted to evaluate the efficacy and safety of t...

Full description

Bibliographic Details
Main Authors:	Jin Zhang, Xiongxiong Fan, Xiaoyu Zhang, Fengli Jiang, Yiping Wu, Beibei Yang, Xinghuan Li, Dong Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-11-01
Series:	Frontiers in Pharmacology
Subjects:	COVID-19 immunomodulators interleukin-6 inhibitors JAK-STAT inhibitors tocilizumab baricitinib
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1293331/full

Similar Items

Baricitinib for the treatment of atopic dermatitis
by: Amelia Melo, et al.
Published: (2022-07-01)

Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
by: Sofia Faria, et al.
Published: (2023-09-01)

Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis
by: Jerin Jose Cherian, et al.
Published: (2022-10-01)

Successful Therapy of Severe and Refractory Cutaneous Sarcoidosis with Baricitinib
by: Giuseppe Russo, et al.
Published: (2024-04-01)

Emerging role of baricitinib in dermatology practice: All we need to know!
by: Sunil Dogra, et al.
Published: (2023-01-01)

Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells
by: Rouven Arnold, et al.
Published: (2021-07-01)

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
by: Kawalec P, et al.
Published: (2019-02-01)

Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study
by: Yuichi Kojima, et al.
Published: (2022-04-01)

Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy
by: M. Tasso, et al.
Published: (2022-12-01)

Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy
by: Yuyang Han, et al.
Published: (2022-10-01)

Role of janus kinase inhibitors in the treatment of alopecia areata
by: Triyangkulsri K, et al.
Published: (2018-07-01)

A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients
by: Wei Bai, et al.
Published: (2023-02-01)

Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
by: Olivia Katamanin, BS, et al.
Published: (2024-01-01)

Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life
by: Valentine Deprez, et al.
Published: (2020-10-01)

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
by: Schlueter M, et al.
Published: (2019-06-01)

Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
by: Giulia Radi, et al.
Published: (2021-11-01)

Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function
by: Iván Parra-Izquierdo, et al.
Published: (2022-04-01)

A green and facile synthesis of an industrially important quaternary heterocyclic intermediates for baricitinib
by: Xin Cui, et al.
Published: (2019-10-01)

Application of Baricitinib in Dermatology
by: Zhang J, et al.
Published: (2022-03-01)

Current views on the pathogenesis and treatment of atopic dermatitis in adults. Experience with the JAK inhibitor baricitinib in patients with moderate to severe atopic dermatitis
by: E. V. Svechnikova, et al.
Published: (2022-04-01)

Baricitinib Lipid-Based Nanosystems as a Topical Alternative for Atopic Dermatitis Treatment
by: Núria Garrós, et al.
Published: (2023-06-01)

Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone
by: Carlos K. H. Wong, et al.
Published: (2022-05-01)

Successful Treatment of Recurrent Adult-Onset Still’s Disease with Tocilizumab: A Case Report and Literature Review
by: Zhong X, et al.
Published: (2023-11-01)

Impact of MnTBAP and Baricitinib Treatment on Hutchinson–Gilford Progeria Fibroblasts
by: Elena Vehns, et al.
Published: (2022-07-01)

Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials
by: Vijairam Selvaraj, et al.
Published: (2022-07-01)

Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study
by: Chan-yuan Wu, et al.
Published: (2023-09-01)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
by: Novin Nezamololama, et al.
Published: (2020-11-01)

Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial
by: Thomas Dörner, et al.
Published: (2022-05-01)

Current Status of Baricitinib as a Repurposed Therapy for COVID-19
by: Maha Saber-Ayad, et al.
Published: (2021-07-01)

Baricitinib attenuates pulmonary fibrosis in scleroderma mice by regulating macrophage polarization
by: WANG Dandan, et al.
Published: (2024-01-01)

Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry
by: Celeste M. Boesjes, et al.
Published: (2022-11-01)

Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study
by: Shuhei Yoshida, et al.
Published: (2023-10-01)

JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis
by: Zhanying Hou, et al.
Published: (2022-06-01)

Baricitinib Liposomes as a New Approach for the Treatment of Sjögren’s Syndrome
by: Núria Garrós, et al.
Published: (2022-09-01)

Corrigendum: JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis
by: Zhanying Hou, et al.
Published: (2023-01-01)

Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
by: Axel De Greef, et al.
Published: (2023-09-01)

Baricitinib Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-β1 Signaling Pathway
by: Songtao Gu, et al.
Published: (2023-02-01)

Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells
by: Chang Liu, et al.
Published: (2019-10-01)

Baricitinib improves pulmonary fibrosis in mice with rheumatoid arthritis-associated interstitial lung disease by inhibiting the Jak2/Stat3 signaling pathway
by: Hongli Liu, et al.
Published: (2023-08-01)

Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial
by: Toshimasa Shimizu, et al.
Published: (2023-03-01)